PolyPeptide Group AG Stock OTC Markets
Stocks
PLYG.F
CH1110760852
Pharmaceuticals
OTC Markets Traded| Market Cap | 1.56B 1.8B 1.45B 1.34B 2.52B 172B 2.57B 17.17B 6.72B 85.27B 6.75B 6.61B 287B | P/E 2026 * |
57.1x | P/E 2027 * | 31.3x |
|---|---|---|---|---|---|
| Enterprise Value | 1.66B 1.92B 1.54B 1.42B 2.68B 183B 2.73B 18.29B 7.16B 90.81B 7.19B 7.03B 305B | EV / Sales 2026 * |
3.38x | EV / Sales 2027 * | 2.98x |
| Free-Float |
39.12% | Yield 2026 * |
-
| Yield 2027 * | 0.07% |
Last Transcript: PolyPeptide Group AG
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 54 | 2023-04-11 | |
Marc Augustin
DFI | Director of Finance/CFO | 54 | 2024-01-01 |
| Chief Tech/Sci/R&D Officer | 54 | - |
| Director | Title | Age | Since |
|---|---|---|---|
Jane Salik
BRD | Director/Board Member | 73 | 2005-12-31 |
Peter Wilden
CHM | Chairman | 69 | 2021-03-31 |
Erik Schropp
BRD | Director/Board Member | 62 | 2020-12-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -.--% | - | - | 1.8B | |
| -1.14% | -4.90% | +53.69% | +150.22% | 1,030B | |
| +0.86% | -2.48% | +55.92% | +53.32% | 617B | |
| -1.47% | -2.37% | +33.96% | +69.29% | 455B | |
| +0.24% | -0.14% | +37.92% | +31.04% | 350B | |
| -0.11% | -0.30% | +34.32% | +38.93% | 299B | |
| -0.51% | -0.03% | +11.85% | +13.23% | 265B | |
| -7.37% | -4.40% | -2.54% | -43.87% | 225B | |
| -1.11% | +1.66% | +29.55% | +63.27% | 209B | |
| -0.70% | +0.84% | +16.13% | +71.26% | 163B | |
| Average | -1.18% | +4.83% | +30.09% | +49.63% | 401.41B | |
| Weighted average by Cap. | -1.02% | +4.87% | +38.78% | +71.99% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 492M 566M 457M 421M 794M 54.06B 808M 5.41B 2.12B 26.85B 2.13B 2.08B 90.3B | 568M 654M 527M 486M 916M 62.41B 933M 6.24B 2.44B 31B 2.46B 2.4B 104B |
| Net income | 23.54M 27.1M 21.86M 20.16M 37.97M 2.59B 38.66M 259M 101M 1.28B 102M 99.54M 4.32B | 43.85M 50.48M 40.72M 37.55M 70.74M 4.82B 72.02M 482M 189M 2.39B 190M 185M 8.05B |
| Net Debt | 101M 117M 94.22M 86.89M 164M 11.15B 167M 1.12B 437M 5.54B 439M 429M 18.63B | 130M 149M 120M 111M 209M 14.25B 213M 1.43B 558M 7.08B 561M 548M 23.81B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
